(Q59799483)

Judith M Gottwein

8

0 references

Jannick Prentoe

Jannick Prentoe

4

0 references

Henrik Krarup

Henrik Krarup

6

0 references

Jens Bukh

Jens Bukh

7

0 references

author name string

Anne F Pihl

1

0 references

Anna F Offersgaard

2

0 references

Christian K Mathiesen

Creative Commons Attribution 4.0 International

3

0 references

language of work or name

English

0 references

publication date

30 November 2018

0 references

published in

Scientific Reports

0 references

volume

8

0 references

issue

1

0 references

page(s)

17505

0 references

copyright license

start time

30 November 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

ICTV Virus Taxonomy Profile: Flaviviridae

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Epidemiology and natural history of HCV infection.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

EASL Recommendations on Treatment of Hepatitis C 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

The importance of resistance to direct antiviral drugs in HCV infection in clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

HCV therapy and risk of liver cancer recurrence: who to treat?

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Complete replication of hepatitis C virus in cell culture

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Three-dimensional culture models for human viral diseases and antiviral drug development.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Cell cultures in drug discovery and development: The need of reliable in vitro-in vivo extrapolation for pharmacodynamics and pharmacokinetics assessment.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Antiviral pharmacodynamics in hollow fibre bioreactors

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (Requirements for biological susbstances no. 50).

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

HCV Genotype 6a Escape from and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Recent advances in technology supporting biopharmaceutical production from mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Bioreactor concepts for cell culture-based viral vaccine production

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Vaccines: correlates of vaccine-induced immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

The development of vaccines: how the past led to the future

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Viral hepatitis: Cell-culture-derived HCV--a promising vaccine antigen

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Production of infectious hepatitis C virus particles in three-dimensional cultures of the cell line carrying the genome-length dicistronic viral RNA of genotype 1b.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Three-dimensional Huh7 cell culture system for the study of Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

3D Cultivation Techniques for Primary Human Hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Modeling Physiological Events in 2D vs. 3D Cell Culture

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

The application of engineered liver tissues for novel drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Degradable thiol-acrylate hydrogels as tunable matrices for three-dimensional hepatic culture

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

A Scalable Perfusion Culture System with Miniature Peristaltic Pumps for Live-Cell Imaging Assays with Provision for Microfabricated Scaffolds

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Increasing 3D Matrix Rigidity Strengthens Proliferation and Spheroid Development of Human Liver Cells in a Constant Growth Factor Environment.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

3D-Printed Gelatin Scaffolds of Differing Pore Geometry Modulate Hepatocyte Function and Gene Expression

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Modulation of Huh7.5 spheroid formation and functionality using modified PEG-based hydrogels of different stiffness

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Direct visualization of hepatitis C virus-infected Huh7.5 cells with a high titre of infectious chimeric JFH1-EGFP reporter virus in three-dimensional Matrigel cell cultures

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Mebiolgel, a thermoreversible polymer as a scaffold for three dimensional culture of Huh7 cell line with improved hepatocyte differentiation marker expression and HCV replication

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Antiviral activity of lanatoside C against dengue virus infection

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Cyclosporine Inhibits Flavivirus Replication through Blocking the Interaction between Host Cyclophilins and Viral NS5 Protein

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Creation of Functional Viruses from Non-Functional cDNA Clones Obtained from an RNA Virus Population by the Use of Ancestral Reconstruction

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Ribavirin-induced mutagenesis across the complete open reading frame of hepatitis C virus genotypes 1a and 3a

2 references

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

PubMed

https://pubmed.ncbi.nlm.nih.gov/30504788

12 December 2020

inferred from PubMed ID database lookup

Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-35010-5

7 January 2021

Three-Dimensional Cell Cultures in Drug Discovery and Development

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30504788

12 December 2020